Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Early Phase 1
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 2(3)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05737433Early Phase 1Completed

Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

Role: lead

NCT05461105Phase 2Completed

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

Role: lead

NCT05402371Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Role: lead

NCT04480710Phase 2Completed

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Role: lead

NCT03596697Phase 1Completed

A Study in Healthy Volunteers

Role: lead

All 5 trials loaded